Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms CPD-141 |
Target |
Action degraders |
Mechanism TrkA degraders(Nerve growth factor receptor Trk-A degraders), TrkB degraders(Neurotrophic tyrosine kinase receptor type 2 degraders), TrkC degraders(Neurotrophic tyrosine kinase receptor type 3 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC54H61F2N9O11 |
InChIKeyWZZQEDKZQHBYFG-UHFFFAOYSA-N |
CAS Registry2412056-89-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 18 May 2020 |